Literature DB >> 16458241

Preventing reactivation of ocular histoplasmosis: guidance for patients at risk.

Richard Trevino1, Ricardo Salvat.   

Abstract

BACKGROUND: Ocular histoplasmosis syndrome (OHS), a significant cause of vision loss in young and middle-aged adults, is associated with the fungus Histoplasma capsulatum (Hc). There is considerable evidence that recurrent reactivation of perimacular ocular histoplasmosis lesions is an important cause of disease progression and that vision loss is at least, in part, a consequence of host sensitivity to fungal antigen.
METHODS: The etiology and pathogenesis of OHS is reviewed and specific recommendations are made for patients with OHS that may decrease the risk of reactivation of ocular histoplasmosis lesions and slow disease progression.
CONCLUSION: Patients with perimacular chorioretinal scars secondary to OHS should be informed by the clinician that they are at risk for vision loss; they should be told the symptoms of choroidal neovascularization and how to self-monitor their vision with an Amsler grid. We recommend they also be instructed on how to decrease their risk of reinfection by Hc. Aggressive treatment of dermatomycoses, onychomycosis, vaginal candidiasis, and other chronic fungal infections may decrease the risk of reactivation of ocular lesions. Patients with OHS who are considering LASIK surgery should be informed that the procedure may trigger choroidal neovascularization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16458241     DOI: 10.1016/j.optm.2005.09.004

Source DB:  PubMed          Journal:  Optometry        ISSN: 1558-1527


  2 in total

1.  The eyes: a window into the past.

Authors:  Nancy F Crum-Cianflone
Journal:  Cleve Clin J Med       Date:  2010-07       Impact factor: 2.321

2.  Multiple Intravitreal Ranibizumab Injections for Persistant Choroidal Neovascularization Associated with Presumed Ocular Histoplasmosis Syndrome.

Authors:  Turgut Yılmaz; Seyhan Dikci; Oğuzhan Genç; Kayhan Mutlu
Journal:  Turk J Ophthalmol       Date:  2017-04-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.